Erratum to: Drugs Ther Perspect (2016) 32(6):265–75 DOI 10.1007/s40267-016-0311-8
Page 267, Table 1, ‘How should it be administered?’ section, ‘Restarting treatment after interruption’ subsection: the cell entry in column 2, which previously read:
“EU/USA: consider administering every 4 weeks”
Should read:
“EU: consider administering every 4 weeks”.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s40267-016-0311-8.
Rights and permissions
About this article
Cite this article
Lyseng-Williamson, K.A. Erratum to: Vedolizumab in moderately to severely active ulcerative colitis or Crohn’s disease: a guide to its use. Drugs Ther Perspect 32, 406 (2016). https://doi.org/10.1007/s40267-016-0327-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-016-0327-0